| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Cobb Stuart | Chief Scientific Officer | C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK | /s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb | 17 Mar 2026 | 0001994301 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NGNE | Common Stock | Sale | $81,456 | -3,991 | -11% | $20.41 | 33,303 | 13 Mar 2026 | Direct | F1, F2, F3 |
| transaction | NGNE | Common Stock | Sale | $56,722 | -2,658 | -8% | $21.34 | 30,645 | 13 Mar 2026 | Direct | F1, F3, F4 |
| transaction | NGNE | Common Stock | Sale | $3,268 | -148 | -0.48% | $22.08 | 30,497 | 13 Mar 2026 | Direct | F1, F3, F5 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. |
| F4 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |